Moreover, the p16-3MR transgenic mouse, a model that contains a p16INK4a promoter which allows the tracing and removal of senescent cells has been used to demonstrate that senescent cell deletion reduces pain in an experimental model of osteoarthritis [68]. This evidence concerns the gene CDKN2A and osteoarthritis.